| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06520 [G. G-R., G. T., T. G. D., M. L. C., D. L. R.], and Department of Pathology, Oviedo University School of Medicine, 33006, Asturias, Spain [A. H.]
ß-catenin is an ubiquitously expressed cytoplasmic protein that has a crucial role in both E-cadherin-mediated cell-cell adhesion and as a downstream signaling molecule in the wingless pathway. Stabilization of ß-catenin followed by nuclear translocation and subsequent T-cell factor/lymphoid-enhancing factor-mediated transcriptional activation has been proposed as an important step in oncogenesis. Stabilization may occur through activating mutations in exon-3 at the phosphorylation sites for ubiquitination and degradation of ß-catenin. Immunohistochemical subcellular localization of ß-catenin and mutational analysis of exon-3 of the ß-catenin gene by single-strand conformational polymorphism followed by DNA sequencing was performed on 37 samples from 31 patients with anaplastic thyroid carcinoma. Immunofluorescent staining showed nuclear localization in 15 (42%) of the 36 samples examined. Nucleotide sequencing of mobility shifts detected by single-strand conformational polymorphism revealed somatic alterations in 19 (61%) of the 31 patients analyzed. We conclude that mutations in ß-catenin are common in anaplastic thyroid cancer and that they may activate transcription, as illustrated by frequent nuclear localization of the protein. These findings support the idea that ß-catenin acts as an oncogene and contributes to the highly aggressive behavior of this tumor.
This article has been cited by other articles:
![]() |
C. J. Guigon, L. Zhao, C. Lu, M. C. Willingham, and S.-y. Cheng Regulation of {beta}-Catenin by a Novel Nongenomic Action of Thyroid Hormone {beta} Receptor Mol. Cell. Biol., July 15, 2008; 28(14): 4598 - 4608. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Li, X. Zhang, R. D. Polakiewicz, T.-P. Yao, and M. J. Comb HDAC6 Is Required for Epidermal Growth Factor-induced {beta}-Catenin Nuclear Localization J. Biol. Chem., May 9, 2008; 283(19): 12686 - 12690. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. De Falco, V. Guarino, E. Avilla, M. D. Castellone, P. Salerno, G. Salvatore, P. Faviana, F. Basolo, M. Santoro, and R. M. Melillo Biological Role and Potential Therapeutic Targeting of the Chemokine Receptor CXCR4 in Undifferentiated Thyroid Cancer Cancer Res., December 15, 2007; 67(24): 11821 - 11829. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Lima, T. Feijao, A. Ferreira da Silva, I. Pereira-Castro, G. Fernandez-Ballester, V. Maximo, A. Herrero, L. Serrano, M. Sobrinho-Simoes, and G. Garcia-Rostan High Frequency of Germline Succinate Dehydrogenase Mutations in Sporadic Cervical Paragangliomas in Northern Spain: Mitochondrial Succinate Dehydrogenase Structure-Function Relationships and Clinical-Pathological Correlations J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4853 - 4864. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. B. Kim, C. J Lewis, K. D McCall, R. Malgor, A. D Kohn, R. T Moon, and L. D Kohn Overexpression of Wnt-1 in thyrocytes enhances cellular growth but suppresses transcription of the thyroperoxidase gene via different signaling mechanisms J. Endocrinol., April 1, 2007; 193(1): 93 - 106. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. A. B. Knostman, S. M. Jhiang, and C. C. Capen Genetic Alterations in Thyroid Cancer: The Role of Mouse Models Vet. Pathol., January 1, 2007; 44(1): 1 - 14. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Garcia-Rostan, A. M. Costa, I. Pereira-Castro, G. Salvatore, R. Hernandez, M. J.A. Hermsem, A. Herrero, A. Fusco, J. Cameselle-Teijeiro, and M. Santoro Mutation of the PIK3CA Gene in Anaplastic Thyroid Cancer Cancer Res., November 15, 2005; 65(22): 10199 - 10207. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Guida, G. Salvatore, P. Faviana, R. Giannini, G. Garcia-Rostan, L. Provitera, F. Basolo, A. Fusco, F. Carlomagno, and M. Santoro Mitogenic Effects of the Up-Regulation of Minichromosome Maintenance Proteins in Anaplastic Thyroid Carcinoma J. Clin. Endocrinol. Metab., August 1, 2005; 90(8): 4703 - 4709. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. E. Nikiforov Anaplastic Carcinoma of the Thyroid--Will Aurora B Light a Path for Treatment? J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 1243 - 1245. [Full Text] [PDF] |
||||
![]() |
M Onda, M Emi, A Yoshida, S Miyamoto, J Akaishi, S Asaka, K Mizutani, K Shimizu, M Nagahama, K Ito, et al. Comprehensive gene expression profiling of anaplastic thyroid cancers with cDNA microarray of 25 344 genes Endocr. Relat. Cancer, December 1, 2004; 11(4): 843 - 854. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Podtcheko, A. Ohtsuru, H. Namba, V. Saenko, and S. Yamashita Authors' Response: Effect of Imatinib Mesylate (Gleevec) on Anaplastic Thyroid Carcinoma Cell Lines J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 5044 - 5044. [Full Text] |
||||
![]() |
O. Marin, V. H. Bustos, L. Cesaro, F. Meggio, M. A. Pagano, M. Antonelli, C. C. Allende, L. A. Pinna, and J. E. Allende Inaugural Article: A noncanonical sequence phosphorylated by casein kinase 1 in {beta}-catenin may play a role in casein kinase 1 targeting of important signaling proteins PNAS, September 2, 2003; 100(18): 10193 - 10200. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Provost, Y. Yamamoto, I. Lizardi, J. Stern, T. G. D'Aquila, R. B. Gaynor, and D. L. Rimm Functional Correlates of Mutations in {beta}-Catenin Exon 3 Phosphorylation Sites J. Biol. Chem., August 22, 2003; 278(34): 31781 - 31789. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. P.A. Ebert, J. Yu, J. Hoffmann, A. Rocco, C. Rocken, S. Kahmann, O. Muller, M. Korc, J. J. Sung, and P. Malfertheiner Loss of Beta-Catenin Expression in Metastatic Gastric Cancer J. Clin. Oncol., May 1, 2003; 21(9): 1708 - 1714. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Adam, T. Danciu, D. L. McLellan, J. G. Borer, J. Lin, D. Zurakowski, M. H. Weinstein, P. H. Rajjayabun, J. K. Mellon, and M. R. Freeman A Nuclear Form of the Heparin-binding Epidermal Growth Factor-like Growth Factor Precursor Is a Feature of Aggressive Transitional Cell Carcinoma Cancer Res., January 15, 2003; 63(2): 484 - 490. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. H. Hwang, J. H. Hwang, H. K. Chung, D. W. Kim, E. S. Hwang, J. M. Suh, H. Kim, K.-H. You, O-Y. Kwon, H. K. Ro, et al. CXC Chemokine Receptor 4 Expression and Function in Human Anaplastic Thyroid Cancer Cells J. Clin. Endocrinol. Metab., January 1, 2003; 88(1): 408 - 416. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Wiseman, T. R. Loree, W. L. Hicks Jr, N. R. Rigual, J. S. Winston, D. Tan, G. R. Anderson, and D. L. Stoler Anaplastic Thyroid Cancer Evolved From Papillary Carcinoma: Demonstration of Anaplastic Transformation by Means of the Inter-Simple Sequence Repeat Polymerase Chain Reaction Arch Otolaryngol Head Neck Surg, January 1, 2003; 129(1): 96 - 100. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-S. Kim, H. Crooks, A. Foxworth, and T. Waldman Proof-of-Principle: Oncogenic {beta}-Catenin Is a Valid Molecular Target for the Development of Pharmacological Inhibitors Mol. Cancer Ther., December 1, 2002; 1(14): 1355 - 1359. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Wolf, M. Rodova, E. A. Miska, J. P. Calvet, and T. Kouzarides Acetylation of beta -Catenin by CREB-binding Protein (CBP) J. Biol. Chem., July 5, 2002; 277(28): 25562 - 25567. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Ishigaki, H. Namba, M. Nakashima, T. Nakayama, N. Mitsutake, T. Hayashi, S. Maeda, M. Ichinose, T. Kanematsu, and S. Yamashita Aberrant Localization of {beta}-Catenin Correlates with Overexpression of Its Target Gene in Human Papillary Thyroid Cancer J. Clin. Endocrinol. Metab., July 1, 2002; 87(7): 3433 - 3440. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. M. Clements, J. Wang, A. Sarnaik, O. J. Kim, J. MacDonald, C. Fenoglio-Preiser, J. Groden, and A. M. Lowy {beta}-Catenin Mutation Is a Frequent Cause of Wnt Pathway Activation in Gastric Cancer Cancer Res., June 1, 2002; 62(12): 3503 - 3506. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Pawlowski, J. R. Ertel, M. P. Allen, M. Xu, C. Butler, E. M. Wilson, and M. E. Wierman Liganded Androgen Receptor Interaction with beta -Catenin. NUCLEAR CO-LOCALIZATION AND MODULATION OF TRANSCRIPTIONAL ACTIVITY IN NEURONAL CELLS J. Biol. Chem., May 31, 2002; 277(23): 20702 - 20710. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. C. Abraham, T.-T. Wu, R. H. Hruban, J.-H. Lee, C. J. Yeo, K. Conlon, M. Brennan, J. L. Cameron, and D. S. Klimstra Genetic and Immunohistochemical Analysis of Pancreatic Acinar Cell Carcinoma : Frequent Allelic Loss on Chromosome 11p and Alterations in the APC/{beta}-Catenin Pathway Am. J. Pathol., March 1, 2002; 160(3): 953 - 962. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. P.A. Ebert, G. Fei, S. Kahmann, O. Muller, J. Yu, J. J.Y. Sung, and P. Malfertheiner Increased {beta}-catenin mRNA levels and mutational alterations of the APC and {beta}-catenin gene are present in intestinal-type gastric cancer Carcinogenesis, January 1, 2002; 23(1): 87 - 91. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Helmbrecht, A. Kispert, R. von Wasielewski, and G. Brabant Identification of a Wnt/{beta}-Catenin Signaling Pathway in Human Thyroid Cells Endocrinology, December 1, 2001; 142(12): 5261 - 5266. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Sadot, B. Geiger, M. Oren, and A. Ben-Ze'ev Down-Regulation of {beta}-Catenin by Activated p53 Mol. Cell. Biol., October 15, 2001; 21(20): 6768 - 6781. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Fujimori, S. Ikeda, Y. Shimizu, M. Okajima, and T. Asahara Accumulation of {beta}-Catenin Protein and Mutations in Exon 3 of {beta}-Catenin Gene in Gastrointestinal Carcinoid Tumor Cancer Res., September 1, 2001; 61(18): 6656 - 6659. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. F. Calvisi, V. M. Factor, R. Loi, and S. S. Thorgeirsson Activation of {beta}-Catenin during Hepatocarcinogenesis in Transgenic Mouse Models: Relationship to Phenotype and Tumor Grade Cancer Res., March 1, 2001; 61(5): 2085 - 2091. [Abstract] [Full Text] |
||||
![]() |
G. Garcia-Rostan, R. L. Camp, A. Herrero, M. L. Carcangiu, D. L. Rimm, and G. Tallini {beta}-Catenin Dysregulation in Thyroid Neoplasms : Down-Regulation, Aberrant Nuclear Expression, and CTNNB1 Exon 3 Mutations Are Markers for Aggressive Tumor Phenotypes and Poor Prognosis Am. J. Pathol., March 1, 2001; 158(3): 987 - 996. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. C. Abraham, B. Nobukawa, F. M. Giardiello, S. R. Hamilton, and T.-T. Wu Sporadic Fundic Gland Polyps : Common Gastric Polyps Arising Through Activating Mutations in the {beta}-Catenin Gene Am. J. Pathol., March 1, 2001; 158(3): 1005 - 1010. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. C. Abraham, E. A. Montgomery, F. M. Giardiello, and T.-T. Wu Frequent {beta}-Catenin Mutations in Juvenile Nasopharyngeal Angiofibromas Am. J. Pathol., March 1, 2001; 158(3): 1073 - 1078. [Abstract] [Full Text] [PDF] |
||||
![]() |
M J Pukkila, J A Virtaniemi, E J Kumpulainen, R T Pirinen, R T Johansson, H J Valtonen, M T Juhola, and V-M Kosma Nuclear {beta} catenin expression is related to unfavourable outcome in oropharyngeal and hypopharyngeal squamous cell carcinoma J. Clin. Pathol., January 1, 2001; 54(1): 42 - 47. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Böhm, L. Niskanen, K. Kiraly, J. Kellokoski, M. Eskelinen, S. Hollmen, E. Alhava, and V.-M. Kosma Expression and Prognostic Value of {{alpha}}-, {beta}-, and {{gamma}}-Catenins in Differentiated Thyroid Carcinoma J. Clin. Endocrinol. Metab., December 1, 2000; 85(12): 4806 - 4811. [Abstract] [Full Text] |
||||
![]() |
J. Kurebayashi, K. Tanaka, T. Otsuki, T. Moriya, H. Kunisue, M. Uno, and H. Sonoo All-Trans-Retinoic Acid Modulates Expression Levels of Thyroglobulin and Cytokines in a New Human Poorly Differentiated Papillary Thyroid Carcinoma Cell Line, KTC-1 J. Clin. Endocrinol. Metab., August 1, 2000; 85(8): 2889 - 2896. [Abstract] [Full Text] |
||||
![]() |
P. Polakis Wnt signaling and cancer Genes & Dev., August 1, 2000; 14(15): 1837 - 1851. [Full Text] |
||||
![]() |
P. W. Schlosshauer, S. A. Brown, K. Eisinger, Q. Yan, E. R. Guglielminetti, R. Parsons, L. H. Ellenson, and J. Kitajewski APC truncation and increased {beta}-catenin levels in a human breast cancer cell line Carcinogenesis, July 1, 2000; 21(7): 1453 - 1456. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. T. Kolligs, B. Kolligs, K. M. Hajra, G. Hu, M. Tani, K. R. Cho, and E. R. Fearon gamma -Catenin is regulated by the APC tumor suppressor and its oncogenic activity is distinct from that of beta -catenin Genes & Dev., June 1, 2000; 14(11): 1319 - 1331. [Abstract] [Full Text] |
||||
![]() |
O. Gimm, A. Perren, L.-P. Weng, D. J. Marsh, J. J. Yeh, U. Ziebold, E. Gil, R. Hinze, L. Delbridge, J. A. Lees, et al. Differential Nuclear and Cytoplasmic Expression of PTEN in Normal Thyroid Tissue, and Benign and Malignant Epithelial Thyroid Tumors Am. J. Pathol., May 1, 2000; 156(5): 1693 - 1700. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Huang, H. Fujii, A. Sankila, B. M. Mahler-Araujo, M. Matsuda, G. Cathomas, and H. Ohgaki {beta}-Catenin Mutations Are Frequent in Human Hepatocellular Carcinomas Associated with Hepatitis C Virus Infection Am. J. Pathol., December 1, 1999; 155(6): 1795 - 1801. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |